• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharmaceutical Executive, January 2023 Issue (PDF)

Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive: January 2023
Volume 43
Issue 01

Click cover to access PDF

Download Issue PDF
Articles in this issue
Key Factors Attributing to a Successful Product Launch
Key Factors Attributing to a Successful Product Launch
Closing the Digital Gap: FDA’s Oversight of Social Media
Closing the Digital Gap: FDA’s Oversight of Social Media
Sales-Rep Compensation: Adding Long-Term Incentives to Mix
Sales-Rep Compensation: Adding Long-Term Incentives to Mix
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
Co-creating New Innovations
Co-creating New Innovations
The Potential Impact of the IRA
The Potential Impact of the IRA
Patient Hubs Continue Growth
Patient Hubs Continue Growth
Social Media’s Complex Climb
Social Media’s Complex Climb
Industry Workforce Seeks Clarity
Industry Workforce Seeks Clarity
Cybersecurity Threats & Pharma
Cybersecurity Threats & Pharma
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Natalie Bickford, chief people officer, Sanofi
Enabling Authenticity
Biopharma Investment Implications: Looking Back and Forward
Biopharma Investment Implications: Looking Back and Forward
Payer Key Business Factors for Orphan Product Launches
Payer Key Business Factors for Orphan Product Launches
Innovating the Go-to-Market Model in Asia
Innovating the Go-to-Market Model in Asia
Recent Videos
Related Content
AstraZeneca, Daiichi Sankyo Submit Biologics License Application of Datopotamab Deruxtecan for Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

AstraZeneca, Daiichi Sankyo Submit Biologics License Application of Datopotamab Deruxtecan for Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

Don Tracy, Associate Editor
November 12th 2024
Article

Decision to submit the Biologics License Application of datopotamab deruxtecan was based on feedback from a previously withdrawn application to the FDA for nonsquamous non-small cell lung cancer.

Key Findings of the NIAGARA and HIMALAYA Trials

Key Findings of the NIAGARA and HIMALAYA Trials

Don Tracy, Associate Editor
November 8th 2024
Podcast

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Gen Li

Solving for Non-Active and Non-Enrolling Sites: Q&A with Dr. Gen Li

Mike Hollan
November 12th 2024
Article

Phesi’s founder and president discusses methods of improving the site selection process.

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Miranda Schmalfuhs
October 25th 2024
Podcast

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

Pharma Pulse 11/12/24: Takeaways From Midlife MS Patients, The Power of Simplicity for First-in-Human Studies & more

Pharma Pulse 11/12/24: Takeaways From Midlife MS Patients, The Power of Simplicity for First-in-Human Studies & more

Miranda Schmalfuhs
November 12th 2024
Article

The latest news for pharma industry insiders.

AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo

AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo

Don Tracy, Associate Editor
November 11th 2024
Article

Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.